Clinical Report: Serum M2BPGi as a Biomarker for Predicting HCC

Overview

This systematic review and meta-analysis demonstrates that elevated serum M2BPGi is significantly associated with the development of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B and C.

Background

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, particularly in patients with chronic viral hepatitis. Current surveillance methods may miss early-stage tumors, highlighting the need for better risk markers. M2BPGi, a serum glycobiomarker, has shown promise in correlating with liver fibrosis and HCC risk.

Data Highlights

Key Findings

• The pooled hazard ratio for HCC associated with elevated M2BPGi is 4.61 (95% CI 3.24–6.54).
• Low heterogeneity was observed in the studies (I2 = 25.6%).
• The association holds across different viral etiologies: CHB (HR 4.12) and HCV (HR 5.07).
• Measurement timing did not significantly affect the association, with baseline HR at 3.21 and post-treatment HR at 5.62.
• Publication bias was indicated by Egger’s test (p = 0.0003), suggesting the true effect may be closer to a 3.5-fold risk increase.

Clinical Implications

The findings indicate a strong association between elevated M2BPGi and HCC risk in patients with chronic hepatitis B and C.

Conclusion

Elevated serum M2BPGi is a strong predictor of HCC development in chronic hepatitis B and C patients.

Related Resources & Content

1. Frontiers | Serum M2BPGi as a predictor of hepatocellular carcinoma development in chronic hepatitis B and C: a systematic review and meta-analysis
2. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
3. The New Gastroenterologist — Innovative Prognostic Model Assesses Hepatocellular Carcinoma Risk in Noncirrhotic Chronic Hepatitis B Patients
4. The New Gastroenterologist — Enhanced Risk Assessment Tool May Optimize HCC Monitoring in Cirrhosis Patients
5. Journal of Gastrointestinal Surgery — Nutritional and Immune-Inflammatory Indices as Predictors of Outcomes in Hepatocellular Carcinoma Patients
6. BMC Gastroenterology — Validity of a seven-gene signature as a non-invasive biomarker for cirrhosis: a cross-sectional study in Egyptian patients with HBV infection
7. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
8. Frontiers | Serum M2BPGi as a predictor of hepatocellular carcinoma development in chronic hepatitis B and C: a systematic review and meta-analysis